<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00804128</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000616972</org_study_id>
    <secondary_id>08755</secondary_id>
    <secondary_id>NCI-2019-07528</secondary_id>
    <secondary_id>R01CA116182</secondary_id>
    <nct_id>NCT00804128</nct_id>
  </id_info>
  <brief_title>Contrast-Enhanced MRI for the Characterization of Ductal Carcinoma in Situ (DCIS)</brief_title>
  <official_title>Contrast-enhanced MRI for the Characterization of Ductal Carcinoma in Situ (DCIS)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of California, San Francisco</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of California, San Francisco</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Diagnostic procedures, such as contrast-enhanced MRI, may help find and diagnose&#xD;
      ductal carcinoma in situ.&#xD;
&#xD;
      PURPOSE: This study is to develop and refine magnetic resonance (MR) imaging methods for&#xD;
      pre-operative staging of ductal carcinoma in situ, a pre-invasive form of breast cancer, and&#xD;
      atypical ductal hyperplasia, a risk factor for developing cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Compare the DCIS optimized MRI to the standard clinical MRI. Using a scale of 1-5 from&#xD;
           poor to excellent, images will be assessed for conspicuity of DCIS and atypical ductal&#xD;
           hyperplasia (ADH) lesions, agreement of disease extent with biopsy, and overall image&#xD;
           quality (artifact level, uniformity of fat suppression, contrast to noise ratio and&#xD;
           signal to noise ratio).&#xD;
&#xD;
        -  Subjects with ADH, a benign condition that can also show enhancement on MRI, will be&#xD;
           enrolled to explore the utility of the DCIS optimized MRI for distinguishing DCIS and&#xD;
           ADH.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 1, 2008</start_date>
  <completion_date type="Anticipated">December 31, 2024</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2024</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Comparison of ductal carcinoma in situ (DCIS)-optimized MRI quality</measure>
    <time_frame>1 month</time_frame>
    <description>Conspicuity of DCIS lesion, agreement of disease extent with biopsy, and overall image quality will be used to determine the overall image quality for each MRI.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Comparison of two DCIS-optimized MRIs for variability in enhancement levels for DCIS</measure>
    <time_frame>1 month</time_frame>
    <description>Conspicuity of DCIS lesion, agreement of disease extent with biopsy, and overall image quality will be used to determine the overall image variability for each MRI.</description>
  </primary_outcome>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Breast Cancer</condition>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>contrast-enhanced magnetic resonance imaging</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gadavist</intervention_name>
    <description>Gadavist injection is a paramagnetic macrocyclic contrast agent administered for magnetic resonance imaging</description>
    <other_name>Gadobutrol</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Subjects with biopsy proven DCIS Subjects with ADH.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Meets 1 of the following criteria:&#xD;
&#xD;
               -  Patient at the University of California, San Francisco Breast Care Center meeting&#xD;
                  the following criteria:&#xD;
&#xD;
                    -  Biopsy proven ductal carcinoma in situ (DCIS) of the breast.&#xD;
&#xD;
                    -  Has undergone mammography within the past 60 days.&#xD;
&#xD;
                    -  ADH patients: over 18, no prior history of breast disease.&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
          -  Not pregnant or nursing (or stopped nursing within the past 3 months)&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  No contraindication to MRI (e.g., implanted pacemaker, implanted ferromagnetic device,&#xD;
             ferromagnetic aneurysm clip, severe claustrophobia, ocular metal fragments, or&#xD;
             shrapnel injury)&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
          -  More than 2 years since prior surgery to the ipsilateral breast (patient)&#xD;
&#xD;
          -  No prior radiotherapy to the ipsilateral breast (patient)&#xD;
&#xD;
          -  No prior cytotoxic regimens (patient)&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nola M. Hylton, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California, San Francisco</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Bonnie Joe, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California, San Francisco</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Nola Hylton, PhD</last_name>
    <phone>877-827-3222</phone>
    <email>cancertrials@ucsf.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of California, San Francisco</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94143</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Margarita Watkins</last_name>
      <phone>877-827-3222</phone>
      <email>cancertrials@ucsf.edu</email>
    </contact>
    <investigator>
      <last_name>Nola Hylton, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>December 5, 2008</study_first_submitted>
  <study_first_submitted_qc>December 5, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 8, 2008</study_first_posted>
  <last_update_submitted>April 30, 2021</last_update_submitted>
  <last_update_submitted_qc>April 30, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 4, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>ductal breast carcinoma in situ</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma in Situ</mesh_term>
    <mesh_term>Carcinoma, Ductal</mesh_term>
    <mesh_term>Carcinoma, Intraductal, Noninfiltrating</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

